Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Gains from Investment Securities (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Gains from Investment Securities readings, the most recent being $200.0 for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities fell 99.92% to $200.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $200.0, a 100.0% decrease, with the full-year FY2025 number at $72290.0, up 338.12% from a year prior.
  • Gains from Investment Securities hit $200.0 in Q1 2026 for Atara Biotherapeutics, up from -$60000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $50.2 million in Q4 2022 to a low of -$60000.0 in Q4 2025.
  • Median Gains from Investment Securities over the past 5 years was $514250.0 (2022), compared with a mean of $4.0 million.
  • Biggest five-year swings in Gains from Investment Securities: surged 1799.77% in 2022 and later plummeted 106.91% in 2025.
  • Atara Biotherapeutics' Gains from Investment Securities stood at $50.2 million in 2022, then crashed by 96.28% to $1.9 million in 2023, then crashed by 53.57% to $868000.0 in 2024, then crashed by 106.91% to -$60000.0 in 2025, then surged by 100.33% to $200.0 in 2026.
  • The last three reported values for Gains from Investment Securities were $200.0 (Q1 2026), -$60000.0 (Q4 2025), and $386068.0 (Q3 2025) per Business Quant data.